AGI reports higher full-year losses

IRISH drug firm AGI Therapeutics has reported a widening of its full-year losses to €14.1m — up from €4.3m in 2006.

Full-year results for 2007, issued yesterday, also show its loss per ordinary share reached 20.9c at the end of last year, up from a loss of 6.9c for the previous 12 months. The firm’s annual revenues rose from €196,000 to €392,000.